Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-0138. [Epub ahead of print]

PMID:
31371343
2.

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.

Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A.

NPJ Precis Oncol. 2019 Jul 16;3:18. doi: 10.1038/s41698-019-0090-5. eCollection 2019.

3.

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology.

Vidula N, Bardia A.

Oncotarget. 2017 Nov 21;8(63):106167-106168. doi: 10.18632/oncotarget.22580. eCollection 2017 Dec 5. No abstract available.

4.

Emerging data on improving response to hormone therapy: the role of novel targeted agents.

Vidula N, Rugo HS.

Expert Rev Anticancer Ther. 2018 Jan;18(1):3-18. doi: 10.1080/14737140.2018.1412259. Epub 2017 Dec 8. Review.

PMID:
29192520
5.
6.

Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.

Rugo HS, Vidula N, Ma C.

Am Soc Clin Oncol Educ Book. 2016;35:e40-54. doi: 10.14694/EDBK_159198. Review.

7.

Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product.

Vidula N, Villa M, Helenowski IB, Merchant M, Jovanovic BD, Meagher R, Mehta J, Singhal S, Winter JN, Frankfurt O, Altman JK, Williams SF, Gordon LI.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e157-62. doi: 10.1016/j.clml.2015.08.085. Epub 2015 Sep 2.

PMID:
26482109
8.

Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.

Vidula N, Rugo HS.

Clin Breast Cancer. 2016 Feb;16(1):8-17. doi: 10.1016/j.clbc.2015.07.005. Epub 2015 Jul 26. Review.

PMID:
26303211
9.

Translating the molecular message of triple-negative breast cancer into targeted therapy.

Vidula N, Rugo HS.

Clin Cancer Res. 2015 Apr 1;21(7):1511-3. doi: 10.1158/1078-0432.CCR-14-2532. Epub 2014 Oct 28.

10.

Encephalopathy and strokes secondary to drug reaction with eosinophilia and systemic symptoms: a case report.

Vidula N, Qamar N, Kurahashi C, Chadha V, Evans D, Peters A.

J Allergy Clin Immunol Pract. 2014 Mar-Apr;2(2):222-4. doi: 10.1016/j.jaip.2013.11.012. No abstract available.

PMID:
24607054
11.

Therapeutic case conference from Northwestern: an elderly gentleman with an unsteady gait.

Vidula N, Johnson M, Didwania A.

Am J Ther. 2012 May;19(3):199-203. doi: 10.1097/MJT.0b013e3182456dd3.

PMID:
22314212
12.

Ultrasound accelerated bone tissue engineering monitored with magnetic resonance microscopy.

Moinnes JJ, Vidula N, Halim N, Othman SF.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:484-8.

PMID:
17946836

Supplemental Content

Loading ...
Support Center